

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1-3. (Canceled)
4. (Previously Presented) The method according to claim 26, wherein the antibody is a modified antibody and wherein said modification is selected from amino acid substitution and chemical modification.
5. (Previously Presented) The method according to claim 26, wherein the antibody is a humanized, human, or chimeric antibody.
6. (Previously Presented) The method according to claim 26, wherein the antibody is produced by the hybridoma deposited as FERM BP-5631.
7. (Previously Presented) The method according to claim 26, wherein the antibody is a monoclonal antibody.
8. (Previously Presented) The method according to claim 26 or 28, wherein the low vasopressin level results from cancer.
9. (Currently Amended) A method of treating at least one symptom caused by a decrease in vasopressin level comprising administering to a patient at least one anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding

fragment thereof, that inhibits the binding between PTHrP and a receptor thereof, allowing the antibody to inhibit the binding of PTHrP and its receptor, and increasing vasopressin level, wherein the antibody, or binding fragment thereof, binds specifically to SEQ ID NO: 75, and wherein the antibody neutralizes parathyroid hormone related protein 1-34.

10. (Previously Presented) The method according to claim 9, wherein the decrease in vasopressin level results from cancer.

11. (Canceled)

12. (Withdrawn) A method of treating hyperosmolarity comprising administering to a patient at least one substance that inhibits the binding between PTHrP and a receptor thereof, allowing the substance to inhibit the binding of PTHrP and its receptor, and increasing vasopressin level.

13. (Withdrawn) The method according to claim 12, wherein the hyperosmolarity is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

14. (Withdrawn) A method for treating dehydration comprising administering to a patient at least one substance that inhibits the binding between PTHrP and a receptor thereof, allowing the substance to inhibit the binding of PTHrP and its receptor, and increasing vasopressin level.

15. (Withdrawn) The method according to claim 14, wherein the dehydration is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

16. (Currently Amended) A method of inhibiting the binding between PTHrP and a receptor thereof comprising providing ~~a substance~~ an anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof, that inhibits the binding between PTHrP and its receptor and allowing the substance to inhibit the binding between PTHrP and its receptor, wherein the antibody, or binding fragment thereof, binds specifically to SEQ ID NO: 75, and wherein the antibody neutralizes parathyroid hormone related protein 1-34, thereby maintaining or increasing low vasopressin levels.

17. (Withdrawn) The method according to claim 16, wherein the substance is an antagonist against a PTHrP receptor.

18. (Canceled)

19. (Currently Amended) The method according to claim 16, wherein the antibody substance is at least one of a fragment of an anti-PTHrP antibody and a modified antibody and wherein said modification is selected from amino acid substitution and chemical modification ~~form of the fragment.~~

20. (Currently Amended) The method according to claim ~~18 or 19~~ 16, wherein the antibody is a humanized, human, or chimeric antibody.

21. (Currently Amended) The method according to claim 20, wherein the antibody is produced by the hybridoma deposited as FERM BP-5631 ~~humanized #23-57-137-1~~ antibody.

22. (Currently Amended) The method according to claim ~~18 or 19~~ 16, wherein the antibody is a monoclonal antibody.

23-24. (Canceled)

25. (Previously Presented) The method according to claim 26, wherein the antibody fragment is Fab, scFv, F(ab')<sub>2</sub>, or Fv.

26. (Currently Amended) A method of maintaining or increasing low vasopressin level comprising administering to a patient at least one anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof, that inhibits the binding between PTHrP and a receptor thereof, allowing the antibody to inhibit the binding of PTHrP and its receptor, and maintaining or increasing vasopressin level, wherein the antibody, or binding fragment thereof, binds specifically to SEQ ID NO: 75, and wherein the antibody neutralizes parathyroid hormone related protein 1-34.

27. (Canceled)

28. (Currently Amended) The method according to claim 4 or 19, wherein the chemical modification is polyethylene glycol (PEG) conjugation ~~or thyroglobulin conjugation.~~